A leading allergy company in Canada has been snapped up by Stallergenes Greer, targeting North America as part of a renewed business development strategy.

Topics are general clinical development issues for immunotherapies targeted at food allergies and respiratory allergic diseases, but recommendations could help move specific products forward for several firms.

Stallergenes Greer Plc., a company specialising in allergy immunotherapy, has appointed Michele Antonelli executive vice president, head of international operations. Prior to Stallergenes Greer, Antonelli held various positions at UCB, with the most recent being executive vice president and head of immunology Europe. Before UCB, Antonelli spent 16 years at Merck Serono, ultimately in the role of senior vice president and global head of biotech manufacturing and process development in Geneva.